Outlook Therapeutics (OTLK) News Today $1.71 -0.06 (-3.62%) As of 01:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OTLK Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of "Moderate Buy" from AnalystsOutlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and four havJune 16 at 3:08 AM | marketbeat.comCFA Institute 2025 Graduate Outlook Survey: Finance Top Career ChoiceJune 12, 2025 | tmcnet.comSteve Wilks Pleased With Jets Defensive OutlookJune 12, 2025 | msn.comOutlook Therapeutics, Inc.: Outlook Therapeutics Announces SMC Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMDJune 10, 2025 | finanznachrichten.deOutlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDJune 10, 2025 | globenewswire.comOilers' Connor McDavid Offers Hilarious Outlook on Crucial Game 1 MomentJune 7, 2025 | msn.comChatGPT Business Features Now Include Gmail/Outlook Connectors, Meeting Transcriptions, New PricingJune 7, 2025 | techrepublic.comOutlook Therapeutics (NASDAQ:OTLK) Given New $21.00 Price Target at Ascendiant Capital MarketsAscendiant Capital Markets dropped their target price on Outlook Therapeutics from $24.00 to $21.00 and set a "buy" rating for the company in a research note on Friday.June 6, 2025 | marketbeat.comOutlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMDJune 2, 2025 | globenewswire.comQ3 EPS Estimate for Outlook Therapeutics Boosted by AnalystOutlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - Analysts at Brookline Capital Management increased their Q3 2025 EPS estimates for shares of Outlook Therapeutics in a research report issued on Tuesday, May 27th. Brookline Capital Management analyst K. Dolliver now forecasts that the compMay 31, 2025 | marketbeat.comBrookline Capital Management Forecasts OTLK FY2026 EarningsOutlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - Brookline Capital Management lowered their FY2026 earnings per share estimates for Outlook Therapeutics in a research report issued on Tuesday, May 27th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will pMay 30, 2025 | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Rating of "Moderate Buy" by AnalystsOutlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and four have given a buy rating toMay 24, 2025 | marketbeat.comOutlook Therapeutics announces public stock offeringMay 24, 2025 | investing.comOutlook Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock and WarrantsMay 24, 2025 | nasdaq.comOutlook Therapeutics announces proposed public offering of common stock, warrantsMay 23, 2025 | msn.comOutlook Therapeutics drops 17%, prices $13M stock offeringMay 23, 2025 | msn.comOutlook Therapeutics® Announces Pricing of $13.0 Million Public OfferingMay 23, 2025 | globenewswire.comOutlook Therapeutics® Announces Proposed Public Offering of Common Stock and WarrantsMay 22, 2025 | globenewswire.comTang Capital Management LLC Has $345,000 Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK)Tang Capital Management LLC trimmed its holdings in Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) by 88.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 182,502 shares of the company's stockMay 21, 2025 | marketbeat.comOutlook Therapeutics, Inc.: Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deOutlook Therapeutics (OTLK) Projected to Post Quarterly Earnings on WednesdayOutlook Therapeutics (NASDAQ:OTLK) will be releasing its Q2 2025 earnings before the market opens on Wednesday, May 21. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-21-outlook-therapeutics-inc-stock/)May 16, 2025 | marketbeat.comOutlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate UpdateMay 15, 2025 | globenewswire.comWant to use both new and classic Outlook apps? Soon, says MicrosoftMay 7, 2025 | msn.comOutlook Therapeutics announces acceptance of BLA by U.S. FDA for ONS-5010April 8, 2025 | markets.businessinsider.comOutlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMDApril 8, 2025 | globenewswire.comOutlook Therapeutics management to meet virtually with BTIGMarch 21, 2025 | markets.businessinsider.comOutlook Therapeutics files to sell 21.72M shares of common stock for holdersMarch 21, 2025 | markets.businessinsider.comOutlook Therapeutics expands share authorizationMarch 16, 2025 | investing.comOutlook Therapeutics Issues Convertible Note to AvondaleMarch 14, 2025 | tipranks.comOutlook Therapeutics files to sell 7.07M shares of common stock for holdersMarch 1, 2025 | markets.businessinsider.comOutlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug AdministrationFebruary 28, 2025 | globenewswire.comResearch Analysts Set Expectations for OTLK Q2 EarningsOutlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for Outlook Therapeutics in a note issued to investors on Tuesday, February 18th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per shaFebruary 21, 2025 | marketbeat.comQ1 Earnings Estimate for OTLK Issued By HC WainwrightOutlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for Outlook Therapeutics in a research note issued to investors on Tuesday, February 18th. HC Wainwright analyst D. Tsao expects that the company will post earningFebruary 20, 2025 | marketbeat.comOutlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceFebruary 19, 2025 | globenewswire.comOutlook Therapeutics price target lowered to $10 from $12 at GuggenheimFebruary 19, 2025 | markets.businessinsider.comOutlook Therapeutics (NASDAQ:OTLK) Given New $3.00 Price Target at HC WainwrightHC Wainwright decreased their price target on shares of Outlook Therapeutics from $30.00 to $3.00 and set a "buy" rating on the stock in a research note on Tuesday.February 19, 2025 | marketbeat.comOutlook Therapeutics' (OTLK) Neutral Rating Reaffirmed at Chardan CapitalChardan Capital reaffirmed a "neutral" rating and issued a $3.00 price objective on shares of Outlook Therapeutics in a research note on Tuesday.February 19, 2025 | marketbeat.comOutlook Therapeutics price target lowered to $3 from $30 at H.C. WainwrightFebruary 18, 2025 | markets.businessinsider.comOutlook Therapeutics (NASDAQ:OTLK) Releases Earnings Results, Misses Estimates By $0.04 EPSOutlook Therapeutics (NASDAQ:OTLK - Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.04).February 15, 2025 | marketbeat.comOutlook Therapeutics (NASDAQ:OTLK) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPSOutlook Therapeutics (NASDAQ:OTLK - Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.04).February 15, 2025 | marketbeat.comOutlook Therapeutics reports Q1 adjusted EPS (89c) vs. (78c) last yearFebruary 14, 2025 | markets.businessinsider.comOutlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate UpdateFebruary 14, 2025 | globenewswire.comOutlook Therapeutics (OTLK) to Release Earnings on WednesdayOutlook Therapeutics (NASDAQ:OTLK) will be releasing earnings before the market opens on Wednesday, February 12, Financial Modeling Prep reports.February 10, 2025 | marketbeat.comAnalysts Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) Price Target at $27.40Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six brokerages that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the companFebruary 10, 2025 | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have issued a buyFebruary 7, 2025 | marketbeat.comOutlook Therapeutics (OTLK) to Release Quarterly Earnings on WednesdayOutlook Therapeutics (NASDAQ:OTLK) will be releasing earnings before the market opens on Wednesday, February 12, Financial Modeling Prep reports.February 5, 2025 | marketbeat.comOutlook Therapeutics® Participates in Virtual Investor “What This Means” SegmentFebruary 4, 2025 | globenewswire.comOutlook Therapeutics names new chairman amid product launchJanuary 31, 2025 | msn.comOutlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of DirectorsJanuary 31, 2025 | globenewswire.comOutlook Therapeutics announces presentation of data from NORSE EIGHTJanuary 23, 2025 | markets.businessinsider.com Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address OTLK Media Mentions By Week OTLK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OTLK News Sentiment▼0.500.90▲Average Medical News Sentiment OTLK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OTLK Articles This Week▼43▲OTLK Articles Average Week Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aardvark Therapeutics News Today Lifecore Biomedical News Today Zhengye Biotechnology News Today Esperion Therapeutics News Today DBV Technologies News Today MediWound News Today Y-mAbs Therapeutics News Today Instil Bio News Today Acelyrin News Today I-Mab News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OTLK) was last updated on 6/17/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OTLK Stock Free OTLK Stock Alerts